Portal de Periódicos da CAPES

Experience with Triple-Drug Therapy in a Pharmacological Erection Program

1993; Lippincott Williams & Wilkins; Volume: 150; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(17)35905-0

1527-3792

Fred E. Govier, R. Dale McClure, Robert M. Weissman, Robert P. Gibbons, Thomas R. Pritchett, Denise Kramer-Levien,

Sexuality, Behavior, and Technology

No AccessJournal of Urology1 Dec 1993Experience with Triple-Drug Therapy in a Pharmacological Erection Program Fred E. Govier, R. Dale McClure, Robert M. Weissman, Robert P. Gibbons, Thomas R. Pritchett, and Denise Kramer-Levien Fred E. GovierFred E. Govier , R. Dale McClureR. Dale McClure , Robert M. WeissmanRobert M. Weissman , Robert P. GibbonsRobert P. Gibbons , Thomas R. PritchettThomas R. Pritchett , and Denise Kramer-LevienDenise Kramer-Levien View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)35905-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail A group of 170 impotent men achieved usable erections during a 26-month period with a combination of papaverine, phentolamine and prostaglandin E1 (triple-drug therapy) injected intracorporeally. Of the patients 146 elected to enter a pharmacological erection program using this combination. Patient age ranged from 24 to 85 years and the average duration on the program was 11.2 months. Average injection volume was 0.36 cc per injection (range 0.1 to 1). Among those patients managed by our nurse clinician, only 3 episodes of priapism were encountered (1.7%). Scarring was documented in 7 of 170 patients (4.2%) 1 week to 21 months after starting the injections. Pain was encountered in 6 of 170 patients (3.5%). A superior dose response coupled with a low incidence of priapism, pain and scarring have led us to use triple-drug therapy as our agent of choice in the pharmacological management of erectile dysfunction. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited bySEXTON W, BENEDICT J and JAROW J (2018) COMPARISON OF LONG-TERM OUTCOMES OF PENILE PROSTHESES AND INTRACAVERNOSAL INJECTION THERAPYJournal of Urology, VOL. 159, NO. 3, (811-815), Online publication date: 1-Mar-1998.Sogari P, Teloken C and Vargas Souto C (2018) ATROPINE ROLE IN THE PHARMACOLOGICAL ERECTION TEST: STUDY OF 228 PATIENTSJournal of Urology, VOL. 158, NO. 5, (1760-1763), Online publication date: 1-Nov-1997.Jarow J and DeFranzo A (2018) Long-Term Results of Arterial Bypass Surgery for Impotence Secondary to Segmental Vascular DiseaseJournal of Urology, VOL. 156, NO. 3, (982-985), Online publication date: 1-Sep-1996.Kim E, El-Rashidy R and McVary K (2018) Papaverine Topical Gel for Treatment of Erectile DysfunctionJournal of Urology, VOL. 153, NO. 2, (361-365), Online publication date: 1-Feb-1995.Govier F, Asase D, Hefty T, McClure D, Pritchett T and Weissman R (2018) Timing of Penile Color Flow Duplex Ultrasonography Using a Triple Drug MixtureJournal of Urology, VOL. 153, NO. 5, (1472-1475), Online publication date: 1-May-1995. (2018) Re: Oral Terbutaline for the Treatment of PriapismJournal of Urology, VOL. 153, NO. 1, (163-164), Online publication date: 1-Jan-1995. Volume 150Issue 6December 1993Page: 1822-1824 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsalprostadilpenile erectionphentolamineimpotencepapaverineMetricsAuthor Information Fred E. Govier More articles by this author R. Dale McClure More articles by this author Robert M. Weissman More articles by this author Robert P. Gibbons More articles by this author Thomas R. Pritchett More articles by this author Denise Kramer-Levien More articles by this author Expand All Advertisement PDF downloadLoading ...